Beam Therapeutics Inc. (BEAM)
Develops genetic medicines that edit diseased cells to treat serious inherited blood and liver disorders.
$25.28+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+34.2%
The outlook
BEAM trades near the lower end of its 52-week range and below both its 50- and 200-day moving averages. Analyst consensus strongly favors the stock, with an average price target roughly double the current level. The overall data picture is mixed, with technical positioning lagging while sentiment remains decidedly bullish.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 13 analysts
Price trendBelow its 50- & 200-day averages
52-week range43% of the way from its 52-week low to high
Price targetAvg target +107% vs current price
Analyst price target
~12-month · 13 analysts$52.31average target+107.0% vs now
Now $25.28
Low $26.00High $80.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.60B
52-wk high
$38.26
52-wk low
$15.60
50-day avg
$30.86
200-day avg
$28.11
Trailing P/E
—